THAT WHICH IS CLAIMED IS:

1. A medicine delivery system comprising:

an outer capsule containing a therapeutically effective amount of krill oil comprising phospholipid bound and triglyceride bound EPA and DHA and the krill oil comprising at least 30% total phospholipids; and

an inner capsule within the outer capsule and containing mixed carotenoids comprising at least S, S'-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin, wherein the outer and inner capsules are formed to prevent mixing of the carotenoids and krill oil until after capsule ingestion.

2. The medicine delivery system according to Claim 1, further comprising 50 to 1000 mg of krill oil contained in the outer capsule.

3. The medicine delivery system according to Claim 1, further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule.

4. The medicine delivery system according to Claim 3, further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

5. The medicine delivery system according to Claim 1, wherein the medicine delivery system is formulated to deliver as a dietary supplement composition formed from the krill oil and mixed carotenoids.

6. A dietary supplement composition that reduces dry eye symptoms in an individual, comprising krill oil containing phospholipid bound and triglyceride bound EPA and DHA in which the krill oil contains at least 30% total phospholipids, 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis*, a reaction product of krill oil and the 3S, 3'S-astaxanthin, and at

least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin, wherein the 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp) is 0.1 to 16 percent by weight of the krill oil in an oral dosage form.

7. The composition according to Claim 6, further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin on a daily basis.

8. The composition according to Claim 7, further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin.

9. The composition according to Claim 6, further comprising 50 to 500 mg of krill oil on a daily basis.

10. The composition according to Claim 6, wherein the dietary supplement composition is formulated into a single dosage capsule.

11. The composition according to Claim 6, wherein the dietary supplement composition is formulated to reduce vision impairments related to cataracts in an individual.

12. The composition according to Claim 6, wherein the dietary supplement composition is formulated to enhance cardiovascular health.

13. A method to reduce dry eye symptoms in an individual by administrating in an oral dosage form a dietary supplement composition comprising krill oil, 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp), a reaction product of krill oil and the 3S, 3'S-astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin, wherein the 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp) is 0.1 to 16 percent by weight of the krill oil.

14. The method according to Claim 13, further comprising administering 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin on a daily basis.

15. The method according to Claim 14, further comprising administering about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin.

16. The method according to Claim 13, further comprising administering krill oil containing phospholipid bound and triglyceride bound EPA and DHA, the krill oil comprising at least 30% total phospholipids.

17. The method according to Claim 13, further comprising administering 50 to 500 mg of krill oil on a daily basis.

18. The method according to Claim 13, wherein the dietary supplement composition is formulated into a single dosage capsule.

19. The method according to Claim 13, wherein the dietary supplement composition is formulated to reduce vision impairments related to cataracts in an individual.

20. The method according to Claim 13, wherein the dietary supplement composition is formulated to enhance cardiovascular health.

CLAIMS

1. A dietary supplement delivery system comprising:

an outer capsule containing a therapeutically effective amount of krill oil comprising phospholipid bound and triglyceride bound EPA and DHA and the krill oil comprising at least 30% total phospholipids; and

an inner capsule within the outer capsule and containing mixed carotenoids comprising at least S, S'-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin, wherein the outer and inner capsules are formed to prevent mixing of the carotenoids and krill oil until after capsule ingestion.

2. The dietary supplement delivery system according to Claim 1, further comprising 50 to 1000 mg of krill oil contained in the outer capsule.

3. The dietary supplement delivery system according to Claim 1, further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule.

4. The dietary supplement delivery system according to Claim 3, further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

5. The dietary supplement delivery system according to Claim 1, wherein the medicine delivery system is formulated to deliver as a dietary supplement composition formed from the krill oil and mixed carotenoids.

6. A dietary supplement composition that reduces dry eye symptoms in an individual, comprising krill oil containing phospholipid bound and triglyceride bound EPA and DHA in which the krill oil contains at least 30% total phospholipids, 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis*, a reaction product of krill oil and the 3S, 3'S-astaxanthin, and at

least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin, wherein the 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp) is 0.1 to 16 percent by weight of the krill oil in an oral dosage form.

7. The composition according to Claim 6, further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin on a daily basis.

8. The composition according to Claim 7, further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin.

9. The composition according to Claim 6, further comprising 50 to 500 mg of krill oil on a daily basis.

10. The composition according to Claim 6, wherein the dietary supplement composition is formulated into a single dosage capsule.

11. The composition according to Claim 6, wherein the dietary supplement composition is formulated to reduce vision impairments related to cataracts in an individual.

12. The composition according to Claim 6, wherein the dietary supplement composition is formulated to enhance cardiovascular health.

13. A method to reduce dry eye symptoms in an individual by administrating in an oral dosage form a dietary supplement composition comprising krill oil, 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp), a reaction product of krill oil and the 3S, 3'S-astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin, wherein the 3S, 3'S-astaxanthin derived from *Haematococcus pluvialis* (Hp) is 0.1 to 16 percent by weight of the krill oil.

14. The method according to Claim 13, further comprising administering 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin on a daily basis.

15. The method according to Claim 14, further comprising administering about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin.

16. The method according to Claim 13, further comprising administering krill oil containing phospholipid bound and triglyceride bound EPA and DHA, the krill oil comprising at least 30% total phospholipids.

17. The method according to Claim 13, further comprising administering 50 to 500 mg of krill oil on a daily basis.

18. The method according to Claim 13, wherein the dietary supplement composition is formulated into a single dosage capsule.

19. The method according to Claim 13, wherein the dietary supplement composition is formulated to reduce vision impairments related to cataracts in an individual.

20. The method according to Claim 13, wherein the dietary supplement composition is formulated to enhance cardiovascular health.